Pulse Biosciences' Shoots For US Clearance Of Nano-Pulse Platform
Executive Summary
Pulse Biosciences' nano-pulse technology, PulseTx, precisely targets and kills cells with short electrical pulses that induce cell death and induce an immunogenic response. The company has submitted a 510(k) application to the US FDA for the technology, seeking a broad soft-tissue ablation indication, but it is developing PulseTx for immunoncology and dermatology indication.
You may also be interested in...
Minute Insight: Medtronic May Sell Respiratory And Monitoring Units To Private Equity
Reuters reported that global private equity firm Carlyle Group has offered to pay at least $7bn for Medtronic’s patient monitoring and respiratory interventions businesses. Medtronic announced its plan to get out of those businesses about one year ago.
‘Build A Company To Be Bought, Not Sold,' 'Match The Asset To The Capital,' And Other Advice From VC Experts
At the recent LSX World Congress USA in Boston, Medtech Insight’s Reed Miller moderated a panel of experienced medtech investors to discuss the current medtech venture financing environment and offer advice for entrepreneurs raising money to support their innovations.
News We’re Watching: Free COVID-19 Tests, Edwards Antitrust Investigation, McKinsey Calls For Medtech ‘Reinvention’
This week, the US government relaunched a program providing free COVID-19 tests and invested $600m in domestic test manufacturing; the European Commission revealed an antitrust investigation of Edwards LifeSciences; and a consulting firm report said the medtech industry should make big changes to address investor skepticism.